Franklin Templeton cuts Syrma SGS stake to 3.01% via open market sale

scanx
Reviewed by
Ritika DScanX News Team
Key Highlights
  • Franklin Templeton Mutual Fund sold 110,190 equity shares of Syrma SGS Technology Ltd on September 30, 2026.
  • The fund's aggregate holding decreased from 3.069% to 3.012% following the open market sale.
  • Franklin India Flexi Cap Fund executed the bulk of the trade, selling 100,197 shares out of the total 110,190.
powered bylight_fuzz_icon
52382899

*this image is generated using AI for illustrative purposes only.

Syrma SGS Technology Ltd witnessed a reduction in institutional ownership as Franklin Templeton Mutual Fund disposed of 110,190 equity shares in the open market on September 30, 2026. This transaction lowered the fund's aggregate stake from 3.069% to 3.012% of the company's total voting capital.

The disclosure was filed under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The seller, Franklin Templeton Mutual Fund, does not belong to the promoter or promoter group. The sale involved only shares carrying voting rights, with no encumbrances or convertible securities involved in the transaction.

Scheme-wise disposal details

The aggregate sale was executed through specific schemes within the Franklin Templeton portfolio. Notably, the Franklin India Flexi Cap Fund accounted for the majority of the divestment, selling over 90% of the total shares disposed by the AMC.

Fund Scheme Pre-sale Holding (Shares) Shares Sold Post-sale Holding (Shares) Post-sale %
Franklin India Opportunities Fund 2,393,073 0 2,393,073 1.241%
Franklin India Multi Cap Fund 1,376,731 0 1,376,731 0.714%
Franklin Small Cap Fund 1,260,845 6,014 1,254,831 0.651%
Franklin India Flexi Cap Fund 413,754 100,197 313,557 0.163%
Franklin India Multi Asset Allocation Fund 273,910 3,979 269,931 0.140%
Franklin Build India Fund 200,000 0 200,000 0.104%
Total 5,918,313 110,190 5,808,123 3.012%

What the numbers show

The data reveals a concentrated exit strategy within the Franklin India Flexi Cap Fund, which sold 100,197 shares, representing approximately 91% of the total 110,190 shares disposed by the AMC. In contrast, major holdings like the Franklin India Opportunities Fund and Franklin India Multi Cap Fund remained unchanged, indicating that the stake reduction was targeted rather than a broad-based liquidation across all schemes. The company's total equity share capital remained static at 192,830,485 shares before and after the transaction.

Historical Stock Returns for Syrma SGS

1 Day5 Days1 Month6 Months1 Year5 Years
-3.65%-0.09%+16.52%+122.21%+123.86%+453.27%

Will other institutional investors follow Franklin Templeton's lead in reducing their exposure to Syrma SGS Technology?

How might the concentrated exit from the Flexi Cap Fund impact the stock's liquidity and short-term price volatility?

Are there upcoming quarterly earnings reports that could influence whether the remaining institutional stakeholders maintain or further reduce their positions?

Syrma Johari MedTech opens Jodhpur medical plastics facility

scanx
Reviewed by
Ashish TScanX News Team
Key Highlights
  • Syrma Johari MedTech inaugurated a 120,000 sq ft medical plastics facility in Jodhpur on September 22, 2026
  • The new plant integrates injection molding, extrusion, blow molding, and tooling capabilities
  • Expansion adds to Syrma SGS Group's network of 17 global production sites and four design centres
powered bylight_fuzz_icon
51603562

*this image is generated using AI for illustrative purposes only.

Syrma Johri MedTech Limited, a subsidiary of syrma sgs , inaugurated a new Medical Plastics and Precision Molding Facility in Jodhpur, Rajasthan on September 22, 2026. The plant spans over 120,000 sq ft and is designed to support global medical-device programmes.

The facility integrates capabilities including injection molding, extrusion, blow molding, and tooling. It will manufacture precision components such as multi-cavity molded parts, diagnostic tubing, and customized profiles for specialized applications.

Strategic Expansion

The Jodhpur site adds to the Syrma SGS Group's existing network of 17 global production sites and four design and innovation centres. This expansion aims to enhance support for customers across the product lifecycle, from design and engineering to manufacturing and assembly.

Sandeep Tandon, Executive Chairman of Syrma SGS Technology Limited, stated that the inauguration reflects a long-term commitment to building specialized manufacturing capabilities in India. He emphasized the facility's role in strengthening the group's ability to serve global MedTech customers.

Operational Capabilities

Syrma Johari MedTech positions itself as a design-led global MedTech CDMO. Its capabilities span design and engineering, precision plastics, tooling, cleanroom operations, and assembly. The company supports programmes in diagnostics, medical aesthetics, patient monitoring, surgical care, critical care, and rehabilitation.

Historical Stock Returns for Syrma SGS

1 Day5 Days1 Month6 Months1 Year5 Years
-3.65%-0.09%+16.52%+122.21%+123.86%+453.27%
Disclaimer: This article is AI-generated using data from LiveSquawk. ScanX is not liable for any inaccuracies.

How will the new facility impact Syrma SGS's market share in the global MedTech CDMO sector?

What are the expected revenue contributions from the Jodhpur plant in the next fiscal year?

Will this expansion lead to similar facilities in other regions to meet growing demand?

More News on Syrma SGS

1 Year Returns:+123.86%